Journals / Selçuk Tıp Dergisi / 2009 / Cilt: 25 - Sayı: 1

Investigation of the efficacy of infliksimab and allopurinol in experimental acute ulcerative colitis model

Deneysel akut ülseratif kolit modelinde infliksimab ve allopurinol'ün etkilerinin incelenmesi

Pages
7–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, we suppose that the decrease in macroscopic and microscopic scores caused by combined medicine use in creases the anti-inflammatory efficacy and that this treatment can be used in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In this study, our purpose was to compare the efficacy of infliximab and allopurinol seperatly and in combined usage in ulcerative colitis.
📊
Key Findings & Data:Material and Methods: 30 Wistar albino rats were used and divided into 5 groups.
💡
Conclusion & Impact:Therefore, we suppose that the decrease in macroscopic and microscopic scores caused by combined medicine use in creases the anti-inflammatory efficacy and that this treatment can be used in the future.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: In this study, our purpose was to compare the efficacy of infliximab and allopurinol seperatly and in combined usage in ulcerative colitis. Material and Methods: 30 Wistar albino rats were used and divided into 5 groups. GROUP I: 1 cc of 4% acetic acid was applied. GROUP II: Similarly, SF solution was applied, GROUP III: After acetic acid application, intraperitoneal infliximab was used, GROUP IV: After acetic acid application, intraperitoneal Allopurinol was used, GROUP V: After acetic acid application, intraperitoneal infliximab+Allopurinol were used. When the rats were under a slight ether anesthesia, a 6-milimetre catheter was placed through anus and 1 cc of 4% acetic acid and SF was applied. The rats in all these groups were sacrificed 48 hours after the procedure. Results: Significant difference (p<0,001) among the groups in terms of their macroscopic and microscopic evaluation was observed. Myeloperoxidase (MPO) scores in infliximab, allopurinol, and combined medicine use groups were close to each other and that they were higher in sham and colitis groups. Malondialdehide (MDA) scores did not show any important difference among the groups. Conclusion: When we consider the macroscopic and microscopic scoring, we believe that the efficiency of allopurinol and infliximab in experimental acute colitis model are close to each other, but lower than the combined medicine use group. Therefore, we suppose that the decrease in macroscopic and microscopic scores caused by combined medicine use in creases the anti-inflammatory efficacy and that this treatment can be used in the future.

Özet

Amaç: Bu çalışmadaki amacımız infliximab ve allopurinol’ün ülseratif kolitteki ayrı ayrı ve birlikte kullanıldıklarındaki etkilerini araştırmaktır. Materyal ve Metod: Çalışmaya 30 adet wistar albino rat alındı ve 5 gruba ayrıldılar. Grup I’e 1 cc %4’lük asetik asid rektal yolla verildi, Grup II’ye aynı mitarda SF verildi, Grup III’e asetik asid ve infliximab verildi, Grup IV’e asetik asid ve allopurinol verildi, Grup V’e asetik asid ve infliximab + allopurinol verildi. Asetik asid ile SF denekler eter anestezisi altındayken rektal yolla sokulan bir kateter aracılığıyla verildi. İlaçlar periton içine enjekte edildiler. Ratlar işlemden 48 saat sonra sakrifiye edildiler. Bulgular: Makroskopik ve mikroskopik incelem sonucu elde edilen skorlar ilaç kullanılan gruplarda anlamlı olarak daha iyi idiler. En iyi sonuç kombine ilaç grubunda bulundu. Miyeloperoksidaz (MPO) değerleri de ilaç kullanılan gruplarda kontrol ve deney grubuna göre anlamlı olarak daha yüksek bulundu. Malondialdehit (MDA) değerleri ise gruplar arasında anlamlı farklılık göstermedi. Sonuç: Mikroskopik ve makroskopik skorlar dikkate alındığı zaman infliximab ve allopurinol’ün deneysel akut ülseratif kolitte düzelme sağladığı ve sonuçların birbirine yakın olduğu gözlendi. Kombine ilaç kullanımının daha etkin bir düzelme sağladığı ve bu yöntemin ülseratif kolit’in tedavisinde kullanılabileceği kanaatine varıldı.

🔖

Cite This Article

AVŞAR, F. M., AYDIN, O. U., ŞAHİN, M., AYDIN, S., PAŞAOĞLU, H., HAN, Ü. (2009). Investigation of the efficacy of infliksimab and allopurinol in experimental acute ulcerative colitis model. Selçuk Tıp Dergisi, Cilt: 25 - Sayı: 1, 7–16. https://ajindex.com/articles/319541

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Jewell DP. Ulcerative colitis. Feldman M, Scharschmidt BF, SIeisenger MH. Sleisenger and Fordtran’s Gastrointestinale and liver diseases. 5th ed. Volum 2. Philadelphia, 1993: 1305-1330 2.Lashner BA. Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North Am. l995: 24(3)
  2. Kirsner JB, Shorter RG. Recent development in “non- specific” inflammatory bowel disease. N Engl J Med 1982
  3. Donaldson RM. Crohn’s disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal disease. 4th ed. Philadelphia: Saunders, 1989: 1327-1358. 5.Wright JP, Mee S., Parfitt A., Marks I.N., et al.: Vi- tamin A therapy in patients with Crohn’s disease. Gastroenterology, 88(2): 512-514,1985. 6.Ahnfelt-Ronne I, Nielson O.H.: The antiinflam- matory moiety of sulfasalazine, 5-ASA, is a radical scavenger. Agents Actions, 21(1-2):191-194,1987. 7.Ahnfelt-Ronne I., Haagen Nielsen O., Chris- tensen A., Langholz E., Binder V., Riis P.: Clinical evidence supporting the scavenger mechanism of 5- aminosalicyclic acid. Gastroenterology, 98: 1162- 1169,1990 8.Fedorak RN,Empey LR,Mc Arthur C,Jevell LD:Miso- prostol provides colonic mucosal protective effect during acetic acid induced colitis in rats.Gastroen- terology J.98
  4. 625,1990 9.Dhawan V, Mohamed A, Fedorak RN. Exercise and inflammatory bowel disease. Can J Gastroenterol. 2009 Jan
  5. 23(1):19-22. Review. 10. Fedorak RW,Empley LR,Walker K. Verapamil alters eicosanoid synthesis and accelerates healing dur- ing experimental colitis in rats.Gastroenterology 1992
  6. 35 11. Okhawa H.,Ohishi N.,Yagi K.:assay for lipid perox- ides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry,95,351-358 (1979). 12. Tianhong Zhang et al
  7. The prophylactic and thera- peutic effects of cholinolytics on perfluoroisobutyl- ene inhalation induced acute lung injury.J Occup Health 2005
  8. 47(4):277-285 13. Barkin JS, Green JA.İnflammatory bowel disease: medical management. In: Berk JE. Haubrich WS, Kalser MH, Roth JLA, Shaffner F.eds. Bockus gastro- enterology. Vol 2.5thed. Philadelphia: J.B.Lippincott, 1994
  9. Farmer RG, Easley KA, Farmer JM. Assessing quality of life for patients with inflammatory bowel disease. Cleve Clin J Med 1992:58
  10. Gerald P., Beck PL, Wallace JL, Fallone CA.: Animal models and pathogenesis of inflammatory bowel disease. Ed: Szabo S, Tache Y, Neuroendocrinol- ogy of Gastrointestinal- Ulceration. Vol 2, 73- 92, Plenium Press, New York, 1995. 16. Watss JN,Dombal